Pernix Therapeutics Holdings

Novus Therapeutics Reports Third Quarter 2019 Financial Results

Wednesday, November 13, 2019 - 12:30pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.
  • We expect results from this study to be available in the first half of 2020.
  • Research and development (R&D) expenses were $1.5 million for the three months ended September 30, 2019, compared to $1.7 million for the same period in 2018.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

Wednesday, November 6, 2019 - 9:05pm

DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday, November 14, 2019.

Key Points: 
  • DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday, November 14, 2019.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 1416459.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDAs 505(b)(2) regulatory pathway.

OnKure Expands Executive Team and Appoints Head of Discovery, Chief Financial Officer and General Counsel

Tuesday, September 24, 2019 - 2:00pm

I am excited to join the OnKure team, a very experienced group with a history of discovering and developing great molecules, said Dr. Winkler.

Key Points: 
  • I am excited to join the OnKure team, a very experienced group with a history of discovering and developing great molecules, said Dr. Winkler.
  • He has over 25 years of executive-level financial expertise, including serving as the Chief Financial Officer for three publicly-traded pharmaceutical companies.
  • Mr. Carruthers joins OnKure from Nivalis Therapeutics (Nasdaq: NVLS), where he served as Interim President, Chief Financial Officer and Secretary.
  • All the new management team members will report directly to Tony Piscopio, Ph.D., OnKures Chief Executive Office and President.

CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference

Tuesday, September 3, 2019 - 12:00pm

ROCKVILLE, Md., Sept. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, announces it will present at the 2019 H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY.

Key Points: 
  • ROCKVILLE, Md., Sept. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, announces it will present at the 2019 H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY.
  • A link to the presentation's webcast as well as a copy of the of the presentation can found on the Company's website www.casipharmaceuticals.com , on September 9, 2019.
  • CASI Pharmaceuticals is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world.
  • CASI has offices in Rockville, Maryland and a wholly owned subsidiary in Beijing, China through which its China operations are conducted.

Novus Therapeutics Reports Second Quarter 2019 Financial Results

Tuesday, August 13, 2019 - 9:05pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2019.
  • The company had $13.7 million in cash as of June 30, 2019.
  • For the six-months ended June 30, 2019, R&D expenses were $5.3 million, compared to $2.4 million for the same period in 2018.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer

Tuesday, July 16, 2019 - 11:30am

Mr. Patel replaces Tamara A. Seymour, who has served as the company's Interim Chief Financial Officer since April 26, 2019.

Key Points: 
  • Mr. Patel replaces Tamara A. Seymour, who has served as the company's Interim Chief Financial Officer since April 26, 2019.
  • "I also want to extend the company's collective thanks to Tamara, a seasoned industry veteran who seamlessly took the helm as Interim Chief Financial Officer after the close of our transaction with Vital Therapies."
  • From 2014 to 2016, Mr. Patel served as Chief Financial Officer of Pernix Therapeutics Holdings, Inc., a holding company that owned several specialty pharmaceutical subsidiaries.
  • Mr. Patel holds a CFA (Chartered Financial Analyst) designation from the CFA Institute and a Bachelor of Science in Biology from McGill University.

Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer

Wednesday, May 8, 2019 - 12:00am

WARREN, N.J., May 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced theappointment of Daniel Barber to the new position of Senior Vice President, Chief Operating Officer (COO) of Aquestive Therapeutics.

Key Points: 
  • WARREN, N.J., May 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced theappointment of Daniel Barber to the new position of Senior Vice President, Chief Operating Officer (COO) of Aquestive Therapeutics.
  • Mr. Barber has worked at Aquestive since 2007, most recently in the role of Senior Vice President, Chief Strategy and Development Officer.
  • In his expanded role as COO, Mr. Barber will also oversee end-to-end product operations, including product development, manufacturing, and quality assurance.
  • Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients.

Currax™ Holdings USA LLC Announces Launch and Close of Acquisition

Wednesday, May 1, 2019 - 2:19pm

Currax Holdings USA LLC is a privately held holding company that wholly owns Currax Pharmaceuticals LLC (Currax) and Persion Pharmaceuticals LLC (Persion), specialty pharmaceutical businesses focused on acquiring and commercializing prescription drugs within the U.S. market.

Key Points: 
  • Currax Holdings USA LLC is a privately held holding company that wholly owns Currax Pharmaceuticals LLC (Currax) and Persion Pharmaceuticals LLC (Persion), specialty pharmaceutical businesses focused on acquiring and commercializing prescription drugs within the U.S. market.
  • Currax Holdings USA LLC was launched simultaneous with the completion of its acquisition of substantially all the assets from Pernix Therapeutics Holdings, Inc. (Pernix).
  • As a result of the acquisition, Currax Holdings USA LLC is now a portfolio company of certain funds managed by Highbridge Capital Management, LLC (Highbridge).
  • Currax Holdings USA LLC is the parent of several subsidiaries, including Currax Pharmaceuticals LLC and Persion Pharmaceuticals LLC, specialty pharmaceutical businesses focused on acquiring and commercializing prescription drugs within the US Market.

Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Thursday, January 3, 2019 - 12:40am

COPENHAGEN, Denmark, Jan. 2, 2019 /PRNewswire/ --Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Mark Hensley to Chief Commercial Officer.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 2, 2019 /PRNewswire/ --Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Mark Hensley to Chief Commercial Officer.
  • Mr. Hensley has served as the Vice-President of Sales for Veloxis Pharmaceuticals, Inc., since May 2017, where he has been responsible for all sales and marketing related functions.
  • Craig Collard, CEO of Veloxis Pharmaceuticals A/S, said, "It is with great pleasure that we promote Mark into the Chief Commercial Officer role.
  • A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.

Rockwell Medical Appoints New Chief Financial Officer

Thursday, November 1, 2018 - 12:00pm

WIXOM, Mich., Nov. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Angus Smith has been appointed as Chief Financial Officer of the Company, effective at the end ofNovember 2018.

Key Points: 
  • WIXOM, Mich., Nov. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Angus Smith has been appointed as Chief Financial Officer of the Company, effective at the end ofNovember 2018.
  • Mr. Smith will join Rockwell Medical from Pernix Therapeutics, a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, where he currently serves as Senior Vice President, Chief Business Officer and Principal Financial Officer.
  • "After conducting a thorough search process, we are very pleased to announce Angus' appointment as CFO of Rockwell Medical," said Stuart Paul, President and Chief Executive Officer of Rockwell Medical.
  • "Angus' deep financial expertise, along with his background advising specialty pharmaceutical and healthcare companies, are a great fit for Rockwell Medical.